# To Evaluate the Clinical Safety and Efficacy of Limbal Stem Cell for Treatment of Superficial Corneal Pathologies".

> **NCT04932629** · EARLY_PHASE1 · UNKNOWN · sponsor: **L.V. Prasad Eye Institute** · enrollment: 20 (estimated)

## Conditions studied

- Corneal Scars and Opacities

## Interventions

- **BIOLOGICAL:** Ex-vivo cultivated Allogeneic limbal stromal stem cells

## Key facts

- **NCT ID:** NCT04932629
- **Lead sponsor:** L.V. Prasad Eye Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07
- **Primary completion:** 2021-12
- **Final completion:** 2023-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04932629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04932629, "To Evaluate the Clinical Safety and Efficacy of Limbal Stem Cell for Treatment of Superficial Corneal Pathologies".". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04932629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*